Ascletis Pharma Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $0.37
50-Day Range
MA: $0.37
52-Week Range
Now: $0.37
Average Volume3,171 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-Ã agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.40 out of 5 stars

Biotechnology Industry

108th out of 146 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASCLF News and Ratings via Email

Sign-up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ascletis Pharma (OTCMKTS:ASCLF) Frequently Asked Questions

What stocks does MarketBeat like better than Ascletis Pharma?

Wall Street analysts have given Ascletis Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ascletis Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Ascletis Pharma's key executives?

Ascletis Pharma's management team includes the following people:
  • Dr. Jinzi Jason Wu, Founder, Chairman & CEO (Age 58)
  • Ms. Hejingdao Wu, VP of Operations & Exec. Director (Age 47)
  • Dr. Handan He Ph.D., Chief Scientific Officer (Age 59)
  • Ms. Yuemei Yan, VP of Sales (Age 51)
  • Dr. Kristjan Sigurdur Gudmundsson, Sr. Consultant & Head of Discovery (Age 53)
  • Dr. George Zhengzhi Hill, Sr. Consultant & Chief Medical Advisor (Age 70)
  • Dr. Melissa Palmer M.D., Chief Medical Officer
  • Mr. Lok Kwan Yim A.C.I.S., A.C.S., Company Sec. (Age 33)

Who are some of Ascletis Pharma's key competitors?

What is Ascletis Pharma's stock symbol?

Ascletis Pharma trades on the OTCMKTS under the ticker symbol "ASCLF."

How do I buy shares of Ascletis Pharma?

Shares of ASCLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascletis Pharma's stock price today?

One share of ASCLF stock can currently be purchased for approximately $0.37.

How many employees does Ascletis Pharma have?

Ascletis Pharma employs 285 workers across the globe.

What is Ascletis Pharma's official website?

The official website for Ascletis Pharma is www.ascletis.com.

This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.